For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Immix Biopharma Inc. (IMMX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Immix Biopharma Inc. is a biotechnology company engaged in developing innovative therapies for oncological and immunotherapy markets. The company focuses on creating cutting-edge treatments by leveraging its proprietary SMARxT Platform to enhance the therapeutic index of drugs. Immix Biopharma's research and development efforts are primarily directed towards treating hematologic and solid tumors, aiming to improve patient outcomes through advanced drug delivery and molecular targeting techniques. The company is involved in multiple stages of drug development, including pre-clinical and clinical trials, to ensure efficacy and safety. Within the financial market, Immix Biopharma represents a critical player in the biotech sector, often seen as part of the broader healthcare and pharmaceuticals industry. By contributing to significant advancements in cancer treatment protocols, Immix Biopharma holds an essential role in pushing the boundaries of traditional cancer therapies, potentially transforming how these life-threatening diseases are managed and treated. With a focus on innovation and patient-centered solutions, Immix Biopharma continues to attract attention from researchers, medical professionals, and investors interested in the expanding field of biotechnology.
Earnings Schedule
Checked daily · calendar updated Aug 9| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | $-0.18 | $-0.18 +0.0% | — | — |
| May 29, 2026 | $0.74 | $0.92 +24.3% | — | — |
| Apr 30, 2026 | $2.03 | $2.68 +32.0% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 7, 2026 | 10-Q | View |
| Jul 20, 2026 | 8-K | View |
| Jun 5, 2026 | SCHEDULE 13G/A | View |
| May 29, 2026 | 8-K | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
| May 29, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 9, 2026 3:01am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.89
Total Equity: $93.80M
Shares: 32,965,706
Total Debt: $0.00
Cash: $93.93M
EBITDA: -$29.71M
Total Debt: $0.00
Cash: $93.93M
Revenue: N/A
Revenue: N/A
Revenue: N/A
Total Equity: $93.80M
Tax Rate: -0.1%
Equity: $93.80M
Total Debt: $0.00
Cash: $93.93M
Current Liabilities: $10.11M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $93.80M
Shares: 32,965,706
Shares: 32,965,706
CapEx: -$732,925
Shares: 32,965,706
Stock Price: $9.72
Net Income: -$29.44M
Income Statement (Annual)
Last updated: Aug 7, 2026 5:20am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $1.4M | $8.2M | $16.1M | $22.7M | $30.0M |
| Operating Income | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M |
| Net Income | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| EBITDA | -$1.3M | -$8.2M | -$16.1M | -$22.6M | -$29.7M |
| EPS | $-6.64 | $-0.15 | $-0.30 | $-0.38 | $-0.89 |
| EPS (Diluted) | — | $-0.15 | $-0.30 | $-0.38 | $-0.89 |
Balance Sheet (Annual)
Last updated: Aug 7, 2026 5:20am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Total Current Assets | $18.2M | $14.9M | $19.8M | $20.2M | $101.2M |
| Total Assets | $18.2M | $14.9M | $19.9M | $22.9M | $104.8M |
| Current Liabilities | $202,039 | $1.3M | $3.7M | $8.7M | $10.1M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $202,039 | $1.7M | $3.7M | $9.7M | $11.0M |
| Total Equity | $18.0M | $13.2M | $16.2M | $13.3M | $93.8M |
| Retained Earnings | -$29.8M | -$38.0M | -$53.4M | -$75.0M | -$104.5M |
Cash Flow (Annual)
Last updated: Aug 7, 2026 5:20am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6M | -$7.4M | -$11.4M | -$14.6M | -$23.9M |
| Capital Expenditure | $-802 | — | $-52,089 | -$1.2M | $-732,925 |
| Free Cash Flow | -$1.6M | — | -$11.4M | -$15.8M | -$24.7M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $200,000 | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | $-99,963 | — | — | — |
| Net Change in Cash | $17.3M | -$4.2M | $4.1M | $172,163 | $76.2M |
Growth Trends (YoY %)
Last updated: Aug 7, 2026 5:20am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -507.9% | -96.4% | -40.5% | -32.1% |
| Net Income Growth | +66.2% | -87.4% | -40.1% | -36.2% |
| EBITDA Growth | -508.9% | -96.4% | -40.3% | -31.2% |
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Narrative Economics
market-narrative step).
Claude Reading
ai-findings step) when a report is run on this ticker.
GPT Reading
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
ext-scorecard step) when a report is run on this ticker.